



**Espacenet**

# Bibliographic data: JP 2004501608 (T)

## VEGF-MODULATED GENES AND METHODS EMPLOYING THEM

**Publication date:** 2004-01-22

**Inventor(s):**

**Applicant(s):**

**Classification:**

**- International:** A01K67/027; A61K39/395; A61K45/00; A61P35/00; A61P43/00; A61P9/00; A61P9/10; C07K14/47; C07K16/18; C12N1/15; C12N1/19; C12N1/21; C12N15/09; C12N15/12; C12N5/10; C12Q1/02; C12Q1/48; C12Q1/68; A61K38/00; (IPC1-7); A01K67/027; A61K39/395; A61K45/00; A61P35/00; A61P43/00; A61P9/00; A61P9/10; C07K14/47; C07K16/18; C12N1/15; C12N1/19; C12N1/21; C12N15/09; C12N5/10; C12Q1/02; C12Q1/48; C12Q1/68

**- European:** C07K14/47

**Application number:** JP20010568372T 20010321

**Priority number(s):** US20000191201P 20000321; WO2001US09043 20010321

**Also published as:**

- [WO 0170174 \(A2\)](#)
- [WO 0170174 \(A3\)](#)
- [WO 0170174 \(A8\)](#)
- [EP 1290005 \(A2\)](#)
- [EP 1290005 \(A4\)](#)
- [more](#)

**Abstract not available for JP 2004501608 (T)**

**Abstract of corresponding document: WO 0170174 (A2)**

The present invention provides methods for modulating angiogenesis and/or apoptosis comprising modulating the activity of at least one VEGF-modulated gene polypeptide. The invention also provides pharmaceutical compositions for modulating angiogenesis and apoptosis for the prevention or treatment of diseases associated with VEGF-modulated genes expression. The invention also provides diagnostic assays that use VEGF-modulated gene polynucleotides that hybridize with naturally occurring sequences encoding VEGF-modulated genes and antibodies that specifically bind to the protein. The invention also provides novel human and mouse arginine-rich proteins (ARPs) and nucleotide sequences. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding ARPs and for a method for producing the protein.

Last updated: 26.04.2011 Worldwide Database 5.7.22; 92p